Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP

Sponsor
Chugai Pharmaceutical
Study ID
NCT00144534
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA213JP.

Key Dates

Start date
Jun 30, 2004
Status verified
Dec 2009
Primary completion
Aug 31, 2005
Completion
Jun 30, 2009

Study Design

Enrollment
115 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Efficacy:the frequency of amelioration of at least 20% in terms of the ACR criteria [ Time Frame: throughout study ]

Related Studies